O-04: INCIDENCE OF VASO-OCCLUSIVE CRISES IN PATIENTS WITH SICKLE CELL DISEASE (SCD) AND A HIGH BASELINE DISEASE BURDEN TREATED WITH CRIZANLIZUMAB IN A REAL-WORLD SETTING: RESULTS FROM A MANAGED ACCESS PROGRAM (MAP)

• SILVA-PINTO A.,
• COLOMBATTI R.,
• PASANISI A.,
• ARCIONI F.,
• DEBONNETT L.,
• SOLIMAN W.,
• SARKAR R.,
• CANÇADO R.

Affiliations

SILVA-PINTO A.

1 Regional Blood Center, Department of Medical Imaging, Hematology and Oncology, Ribeirão Preto School of Medicine, São Paulo, BRAZIL

COLOMBATTI R.

2 Azienda Ospedale-Università di Padova, Padova, ITALY

PASANISI A.

3 Centro Microcitemia-UOC, Ematologia con trapianto, PO Perrino, Brindisi, ITALY

ARCIONI F.

4 Pediatric Hematology and Oncology with Bone Marrow Transplantation, Azienda Ospedaliera di Perugia, Perugia, ITALY

DEBONNETT L.

5 Novartis Pharmaceuticals Corporation, East Hanover, UNITED STATES

SOLIMAN W.

6 Novartis Saudi Ltd, Riyadh, SAUDI ARABIA

SARKAR R.

7 Novartis Healthcare Pvt. Ltd., Hyderabad, INDIA

CANÇADO R.

8 Department of Hematology and Oncology, Santa Casa de São Paulo School of Medicine, São Paulo, BRAZIL